Prechoroidal Cleft Regression After Switch to Intravitreal Brolucizumab.
Paolo ForteLorenzo Ferro DesideriRiccardo ManocchioPaolo CorazzaCarlo Enrico TraversoMassimo NicolòPublished in: European journal of ophthalmology (2023)
To our knowledge, this case report is the first to analyze the clinical efficacy of brolucizumab targeting prechoroidal clefts. Clinical implication and pathogenesis of prechoroidal clefts are yet to be fully elucidated.